1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. BIOANALYTICAL TESTING MARKET BY MOLECULE TYPE
5.1. Introduction
5.2. Small Molecule
5.3. Large Molecule
6. BIOANALYTICAL TESTING MARKET BY ANALYSIS TYPE
6.1. Introduction
6.2. Discovery Bioanalysis
6.3. Pre-Clinical Bioanalysis
6.4. Clinical Bioanalysis
7. BIOANALYTICAL TESTING MARKET BY SAMPLE TYPE
7.1. Introduction
7.2. Blood
7.3. Urine
7.4. Saliva
7.5. Plasma
7.6. Others
8. BIOANALYTICAL TESTING MARKET BY APPLICATION
8.1. Introduction
8.2. Oncology
8.3. Neurology
8.4. Immunology
8.5. Metabolic Disorder
8.6. Infectious Disease
8.7. Others
9. BIOANALYTICAL TESTING MARKET BY END-USER
9.1. Introduction
9.2. Pharmaceuticals & Biotech Company
9.3. Contract Research Organization
9.4. Others
10. BIOANALYTICAL TESTING MARKET BY GEOGRAPHY
10.1. Introduction
10.2. North America
10.2.1. USA
10.2.2. Canada
10.2.3. Mexico
10.3. South America
10.3.1. Brazil
10.3.2. Argentina
10.3.3. Others
10.4. Europe
10.4.1. Germany
10.4.2. France
10.4.3. United Kingdom
10.4.4. Spain
10.4.5. Others
10.5. Middle East and Africa
10.5.1. Saudi Arabia
10.5.2. UAE
10.5.3. Israel
10.5.4. Others
10.6. Asia Pacific
10.6.1. China
10.6.2. India
10.6.3. Japan
10.6.4. South Korea
10.6.5. Indonesia
10.6.6. Thailand
10.6.7. Others
11. COMPETITIVE ENVIRONMENT AND ANALYSIS
11.1. Major Players and Strategy Analysis
11.2. Market Share Analysis
11.3. Mergers, Acquisitions, Agreements, and Collaborations
11.4. Competitive Dashboard
12. COMPANY PROFILES
12.1. Thermo Fisher Scientific Inc.
12.2. ICON Plc
12.3. Charles River Laboratories International, Inc
12.4. IQVIA Holdings, Inc.
12.5. Syneos Health
12.6. SGS SA
12.7. Intertek Group Plc
12.8. Pace Analytical
12.9. Eurofins Scientific SE
12.10. BioPharma Services Inc.
13. APPENDIX
13.1. Currency
13.2. Assumptions
13.3. Base and Forecast Years Timeline
13.4. Key benefits for the stakeholders
13.5. Research Methodology
13.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES